Trial Profile
Phase II Study of Nilotinib in Metastatic Melanoma With KIT Aberrations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2016
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 28 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 09 Apr 2010 New trial record